Comparing Immunic (NASDAQ:IMUX) & Erasca (NASDAQ:ERAS)

Erasca (NASDAQ:ERAS) and Immunic (NASDAQ:IMUX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Volatility & Risk

Erasca has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

67.8% of Erasca shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Erasca and Immunic”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55 million	($0.93)	-19.92
Immunic	N/A	N/A	-$97.17 million	($5.58)	-2.65

Erasca is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Erasca and Immunic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Immunic	N/A	-220.75%	-132.04%

Analyst Ratings

This is a summary of current ratings for Erasca and Immunic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1	2	7	0	2.60
Immunic	1	1	6	3	3.00

Erasca presently has a consensus price target of $20.11, indicating a potential upside of 8.53%. Immunic has a consensus price target of $47.57, indicating a potential upside of 222.08%. Given Immunic’s stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Erasca.

About Erasca

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.